Oncolytic Virus Market Summary

• The Oncolytic Virus Therapies Market is gaining momentum as researchers increasingly explore viruses that selectively target and destroy cancer cells while stimulating the patient’s immune response.
• The leading Oncolytic Virus Therapies Companies include Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others.

Oncolytic Virus Therapies Market Trends and Insights

• Oncolytic viruses, which are known for infecting cancer cells, flourish inside these cells where they replicate quickly, causing cell destruction by bursting them open and exposing their contents to the immune system.
• Clinical trials have shown that OVs can kill cancer cells resistant to conventional therapies, potentially overcoming these challenges. To date, only two oncolytic viruses have received regulatory approval. Talimogene laherparepvec (T-VEC), marketed as IMLYGIC, is approved in the US and Europe for the treatment of melanoma. In Japan, DELYTACT has been approved as a regenerative medicine for malignant glioma.
• A diverse array of OVs are currently in clinical development, with ongoing research focusing on factors such as route of administration and optimal combinations. Most trials are still in early phases, but the flexibility and specificity of OVs hold promise for regulatory approval.
• Combining oncolytic viruses with anti‐checkpoint antibodies such as anti‐PD‐1, anti‐PDL‐1, and anti‐CTLA4 or CAR‐T cells can be effective in cancer therapy in a synergistic fashion.
• Positive clinical trial results in treating melanomas, glioblastoma, ovarian cancer, pancreatic cancers, and many other solid tumors have significantly advanced the development of targeted therapies, including emerging oncolytic viruses.
• Active FDA involvement in oncolytic therapy and companies' collaboration signifies an upcoming advancement in the oncolytic virus therapy landscape and a huge change in cancer treatment with less side effects.
• The Oncolytic Virus Therapies Pipeline is rapidly expanding, with Genelux, Candel Therapeutics, CG Oncology, Lokon Pharma, Bioinvent, Istari Oncology, and many others leading the charge.

Request for unlocking the sample page of the “Oncolytic Virus Therapies Market”

Key Factors Driving the Growth of the Oncolytic Virus Cancer Therapy Market 

• Growing Adoption of Novel Cancer Immunotherapies

The increasing shift toward innovative immuno-oncology approaches is driving interest in oncolytic virus therapies. These treatments can selectively infect and destroy tumor cells while also stimulating broader antitumor immune responses.

• Rising Cancer Burden Worldwide

The growing incidence of cancer and the need for more effective treatment options are creating demand for alternative therapeutic modalities. Oncolytic viruses offer a promising approach, particularly for patients with advanced or treatment-resistant cancers.

• Advancements in Viral Engineering Technologies

Progress in genetic engineering is enabling the development of more targeted and potent oncolytic viruses. Researchers can modify viral platforms to improve tumor selectivity, enhance immune activation, and deliver therapeutic genes directly to cancer cells.

• Increasing Clinical Development and Pipeline Activity

Pharmaceutical and biotechnology companies are expanding their oncolytic virus therapy pipelines across multiple tumor types. Growing clinical trial activity of therapies such as Cretostimogene grenadenorepvec (CG Oncology), CAN-2409 (Candel Therapeutics), AdAPT-001 (EpicentRx), LOAd703 (Lokon Pharma), RP1 (Replimune), VG 161 (Virogin Biotech), and others, and encouraging efficacy data are supporting greater investment and market interest.

DelveInsight’s “Oncolytic Virus Therapies Market Size, Target Population, Competitive Landscape, and Market Forecast – 2036” report delivers an in-depth understanding of the Oncolytic Virus Therapies, historical and Competitive Landscape as well as the oncolytic virus therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Oncolytic Virus Therapies Market Report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM oncolytic virus therapies market size from 2022 to 2036. The report also covers current oncolytic virus therapies treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Oncolytic Virus Therapies Understanding

Oncolytic Virus Therapies Overview

Oncolytic viral therapy is a treatment using a virus that can replicate to kill cancer cells. Many virus species exist, but not all can be designed to function as oncolytic viruses. Key characteristics of oncolytic viruses include non-pathogenicity, the ability to target and kill cancer cells specifically, and the potential to be genetically modified to express tumor-killing factors.

Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication. The OV field gained considerable attention after positive results from many clinical trials. So far, four oncolytic viruses have been approved globally.

• The first OV, a picornavirus called RIGVIR, was approved in Latvia to treat melanoma but never achieved widespread use.
• Secondly, an engineered adenovirus, designated H101, was approved in China in 2005 to treat head and neck cancer. 
• Thirdly, in 2015, another oncolytic virus, an engineered Herpes Simplex Virus (HSV-1), named IMLYGIC (talimogene laherparepvec, (T-VEC)), was approved in the US and Europe for the treatment of non-resectable metastatic melanoma. Finally, in 2021, a modified herpes simplex virus, named DELYTACT, was approved in Japan for brain cancers such as glioblastoma.

Oncolytic Virus Therapies Treatment

n the coming decade, the oncolytic virus therapies landscape represents a huge potential for the pharmaceutical sector. Oncolytic virotherapy treatments, particularly in areas such as brain cancer, skin cancer, prostate cancer, and other kinds, have already begun to achieve therapeutic millstones as a result of recent advancements.

Oncolytic viruses represent a promising frontier in oncolytic virus therapies for cancer therapy, harnessing the power of natural agents to seek out and eradicate malignant cells. These viruses possess an inherent preference for infiltrating, replicating within, and ultimately destroying cancer cells while sparing normal tissue.

Whether occurring naturally or engineered for enhanced efficacy, oncolytic viruses exhibit remarkable tumor selectivity, exploiting the unique vulnerabilities of cancer cells to trigger their demise. The therapeutic strategy of oncolytic virus therapy hinges on a dual mechanism: first, the targeted infection of tumor cells, followed by the induction of potent antitumor responses through the release of tumor antigens and stimulation of the host immune system. This process entails oncolytic viruses replicating within tumor cells, culminating in their lysis and the subsequent release of progeny virions, which can further propagate the infection to adjacent cancer cells, amplifying the cycle of cancer cell death.

Ultimately, oncolytic virus therapies hold great promise as a multifaceted approach that not only directly targets tumors but also mobilizes the immune system against cancer, offering a potent arsenal in the fight against malignancy.

Oncolytic Virus Therapies Market Recent Breakthroughs and Developments

• In August 2026, Replimune Group Inc. announced that the FDA has granted accelerated approval to TUDRIQEVTM (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with an anti-PD-1 antibody-based regimen.
• In July 2026, UroGen Pharma Ltd. announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation investigational oncolytic virus. The IND clearance paves the way for the initiation of a planned Phase 1 clinical trial evaluating UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC).
• In June 2026, Candel Therapeutics, Inc. initiated the global pivotal Phase 3 AURORA trial (NCT07660094) to evaluate aglatimagene besadenovec (aglatimagene; CAN-2409) plus valacyclovir alongside continued pembrolizumab treatment in patients with metastatic non-squamous NSCLC who experienced disease progression following pembrolizumab and platinum-based chemotherapy.
• In May 2026, CG Oncology reported positive Phase II CORE-008 Cohort CX results, with cretostimogene grenadenorepvec plus gemcitabine demonstrating encouraging high-grade event-free survival (HG-EFS), high complete response (CR) rates, and favorable tolerability in high-risk NMIBC patients. The data, which demonstrate encouraging HG-EFS, high CR rates, and a well-tolerated safety profile, were presented at the Society of Urologic Oncology (SUO) Session at the 2026 American Urological Association (AUA) Annual Meeting.
• In March 2026, Genelux reported positive clinical progress for Olvi-Vec, with Phase III ovarian cancer topline data expected in 2H26, encouraging lung cancer results, and cash runway extending into 1Q27.
• In February 2026, CG Oncology reported accelerated enrollment and an expedited Phase III (PIVOT-006) timeline in intermediate-risk NMIBC, with topline data expected in 1H26. The company also reported strong efficacy and durability data for cretostimogene across high-risk NMIBC cohorts, announced upcoming Phase II combination results with gemcitabine, and remains on track for a BLA submission in high-risk BCG-unresponsive NMIBC during 2026.

Oncolytic Virus Therapies Drug Analysis

The drug chapter segment of the oncolytic virus therapies reports encloses a detailed analysis oncolytic virus therapies marketed drugs and late-stage (Phase III and Phase II) Oncolytic Virus Therapies pipeline drugs. It also helps understand the oncolytic virus therapies' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug the latest news and press releases.

Oncolytic Virus Therapies Marketed Drugs

• IMLYGIC (talimogene laherparepvec): Amgen

IMLYGIC is a genetically modified HSV-1 designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF). IMLYGIC causes cell lysis, or death, which ruptures tumors, releasing tumor-derived antigens, which, along with GM-CSF, may promote an antitumor immune response; however, the exact mechanism of action is unknown. In October 2015, the FDA approved IMLYGIC for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery, an In December 2015, the European Commission approved for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC, and IVM1a), with no bone, brain, lung or other visceral disease.

• DELYTACT (teserpaturev/G47Δ): Daiichi Sankyo

DELYTACT (teserpaturev/G47∆) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1). DELYTACT has triple mutation within the viral genome that causes augmented and selective replication in cancer cells and enhanced induction of antitumor immune response while retaining high safety features. DELYTACT is currently the first third-generation oncolytic HSV-1 to be evaluated in humans. In June 2021, Daiichi Sankyo received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for DELYTACT (teserpaturev/G47∆), an oncolytic virus, for the treatment of patients with malignant glioma. It has received 

Note: Detailed current therapies assessment will be provided in the full report of oncolytic virus therapies

Oncolytic Virus Therapies Emerging Drugs

• Olvi-Vec (Olvimulogene nanivacirepvec): Genelux

Olvi-Vec is a modified vaccinia virus that utilizes a triple mode of action: it directly kills cancer cells, stimulates a tumor-specific immune response, and converts the tumor microenvironment from an immunosuppressive (cold state) to an immunoreactive (hot state). Currently, it is in clinical development for the treatment of ovarian cancer (resistant/refractory) and recurrent non-small cell lung cancer (NSCLC) in the US and China. Also, it is under clinical development for the same indication along with SCLC (recurrent). The US FDA has granted Fast Track Designation for the development program of olvi-vec for the treatment of patients with platinum-resistant/refractory ovarian cancer.

• CG-0070 (Cretostimogene grenadenorepvec): CG Oncology

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase III clinical trial for the treatment of Bacillus Calmette–Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Cretostimogene is also being evaluated in a Phase III monotherapy clinical trial (PIVOT-006) in intermediate-risk NMIBC patients. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle-invasive bladder cancer. 

Note: Detailed emerging therapies assessment will be provided in the final report.

Note: The emerging drug list is indicative, the full list will be given in the final report.

Oncolytic Virus Therapies Market Outlook 

To date, only four oncolytic viruses have been approved for use as cancer treatments, though many more are currently in development. Several oncolytic viruses have been discontinued either due to insufficient efficacy or due to unacceptable toxicity. Developing oncolytic viruses presents numerous challenges, which may contribute to the difficulty in achieving regulatory approval.

In 2015, T-VEC (IMLYGIC), a genetically engineered HSV-1, became the first oncolytic virus approved in the USA for advanced unresectable melanoma and was subsequently approved in Europe. The most recent oncolytic virus, a modified HSV-1 called teserpaturev or G47Δ (DELYTACT), received conditional and time-limited approval in Japan in June 2021 for malignant gliomas. However, DELYTACT has not been approved in the United States.

The Oncolytic Virus Therapies Emerging Therapies include olvimulogene nanivacirepvec, CAN-2409, cretostimogene grenadenorepvec, RP1, VG161, AdAPT-001, Voyager-V1, pelareorep, VCN-01, Pexa-Vec, delolimogene mupadenorepvec, BT-001, and T3011, which are currently in Phase III, Phase II, and Phase I/II trials.

The oncolytic virus therapy market is set for significant growth, providing new hope and innovative methods to combat cancer. The rapid pace of ongoing research, combined with collaborative efforts among scientists, clinicians, and industry stakeholders, will play a crucial role in shaping the future of this promising field in the forecast period (2024–2034). Advances in viral engineering, genetic modification, and personalized medicine are driving the development of more effective and targeted therapies. 

Oncolytic Virus Therapies Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging oncolytic virus therapies expected to be launched in the market during 2022–2036.

Oncolytic Virus Therapies Clinical Development Activities

The Oncolytic Virus Therapies Market Report provides insights into different therapeutic candidates in Phase III, and Phase II. It also analyzes key players involved in developing targeted therapeutics. The presence of numerous drugs under different stages is expected to generate immense opportunity for oncolytic virus therapies market growth over the forecasted period.

Oncolytic Virus Therapies Pipeline Development Activities

The Oncolytic Virus Therapies Market Report covers information on collaborations, acquisitions and mergers, licensing, and patent details for oncolytic virus therapies emerging therapies. The increasing strategic collaborations among major market players to enhance the growth of their pipeline products are anticipated to drive market expansion. 

Latest KOL Views on Oncolytic Virus Therapies

To keep up with current and future Oncolytic Virus Therapies Market Trends, we take Industry Experts’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on oncolytic virus therapies' evolving treatment landscape, patient reliance on conventional therapies, patient therapies switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight’s analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. 

Their opinion helps understand and validate current and emerging therapies treatment patterns or oncolytic virus therapies market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Oncolytic Virus Therapies Report Qualitative Analysis

We perform Qualitative and Oncolytic Virus Therapies Market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving Oncolytic Virus Therapies Treatment landscape.

Oncolytic Virus Therapies Market Access and Reimbursement

IMLYGIC

IMLYGIC (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on the skin or in lymph glands. IMLYGIC is a weakened form of herpes simplex virus type 1, which is commonly called the cold sore virus. The doctor will inject IMLYGIC directly into the tumor.

Amgen SupportPlus Copay Program

The Amgen SupportPlus Copay Program helps eligible commercially insured patients pay for their out-of-pocket prescription costs.

• Pay as little as USD 0 out-of-pocket for each dose or cycle
• Can be applied to deductible, co-insurance, and co-payment
• No income eligibility requirement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The abstract list is not exhaustive, will be provided in the final report

Scope of the Oncolytic Virus Therapies Market Report

• The Oncolytic Virus Therapies Market Report covers a segment of key events, an executive summary, and a descriptive overview, explaining its mechanism and therapies (current and emerging).
• Comprehensive insight into the Oncolytic Virus Therapies Competitive Landscape and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging Oncolytic Virus Therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the Oncolytic Virus Therapies Market, historical and forecasted Oncolytic Virus Therapies market size, Oncolytic Virus Therapies market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Oncolytic Virus Therapies Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis expert insights/KOL views, and treatment preferences that help shape and drive the 7MM oncolytic virus therapies market.

Oncolytic Virus Therapies Market Report Insights

• Oncolytic Virus Therapies Targeted Patient Pool
• Oncolytic Virus Therapies Therapeutic Approaches
• Oncolytic Virus Therapies Pipeline Analysis
• Oncolytic Virus Therapies Market Size and Trends
• Existing and Future Market Opportunity

Oncolytic Virus Therapies Market Report Key Strengths

• 11-Year Oncolytic Virus Therapies Market Forecast
• The 7MM Coverage 
• Key Cross Competition 
• Drugs Uptake and Key Market Forecast Assumptions

Oncolytic Virus Therapies Market Report Assessment

• Current Oncolytic Virus Therapies Treatment Practices
• Oncolytic Virus Therapies Unmet Needs
• Oncolytic Virus Therapies Pipeline Product Profiles
• Oncolytic Virus Therapies Market Attractiveness
• Oncolytic Virus Therapies Qualitative Analysis (SWOT)

Key Questions Answered in the Oncolytic Virus Therapies Market Report

• What was the oncolytic virus therapies market size, the Oncolytic Virus Therapies market size by therapies, Oncolytic Virus Therapies market share (%) distribution, and what would it look like in 2036? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2036?
• Which is the most lucrative market for oncolytic virus therapies?
• What are the pricing variations among different geographies for approved therapies?
• How has the reimbursement landscape for oncolytic virus therapies evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with oncolytic virus therapies? What will be the growth opportunities across the 7MM for the patient population on oncolytic virus therapies?
• What are the key factors hampering the growth of the oncolytic virus therapies market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for oncolytic virus therapies?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to Buy the Oncolytic Virus Therapies Market Report

• The Oncolytic Virus Therapies Market Report will help develop business strategies by understanding the latest trends and changing dynamics driving the oncolytic virus therapies Market.
• Understand the existing Oncolytic Virus Therapies Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the Oncolytic Virus Therapies Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and Oncolytic Virus Therapies emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Stay updated with us for Recent Articles

• Top 7 Emerging Vaccinia Virus-associated Oncolytic Virus Therapies
• 7 HSV-associated Oncolytic Virus Therapies in Late and Mid-Stage
• 8 Late and Mid-Stage Adenovirus-associated Oncolytic Virus Therapies to Watch Out For
• 15 Prominent Indications for Oncolytic Virus Therapy
• New DelveInsight Blogs